{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:06:25Z","timestamp":1777489585742,"version":"3.51.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Voriconazole (VRCZ) is an antifungal triazole recommended as an effective first-line agent for treating invasive aspergillosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To develop a population pharmacokinetic model of VRCZ and trough concentration-based dosing simulation for dynamic patient conditions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The authors combined plasma VRCZ data from intensive sampling, and retrospective trough concentration monitoring for analysis. Nonlinear mixed-effects modeling with subsequent model validation was performed. The recommended dosage regimens were simulated based on the developed model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The study participants included 106 patients taking oral VRCZ. A linear one-compartment model with first-order elimination and absorption best described the observed data. The CYP2C19 phenotypes did not influence the pharmacokinetic parameters. Serum albumin (SA) levels and gamma-glutamyl transferase significantly correlated with the VRCZ clearance rate, whereas the actual body weight influenced the volume. A visual predictive check showed good consistency with the observed data, whereas SA levels across the treatment course correlated with linear clearance, irrespective of the CYP2C19 phenotype. Patients with SA levels \u226430 g\/L had lower linear clearance than that in patients with SA levels &gt;30 g\/L. Dosing simulation based on the developed model indicated that patients with SA levels of \u226430 g\/L required a lower daily maintenance dose to attain the therapeutic trough level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>SA level was identified as a novel marker associated with VRCZ clearance. This marker may be a practical choice for physicians to perform therapeutic drug monitoring and optimize VRCZ dosage.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000799","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T22:05:51Z","timestamp":1600812351000},"page":"872-879","source":"Crossref","is-referenced-by-count":30,"title":["Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization"],"prefix":"10.1097","volume":"42","author":[{"given":"Prawat","family":"Chantharit","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan;"},{"name":"Deparment of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montira","family":"Tantasawat","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Srinakharinwirot University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1248\/bpb.b14-00768","article-title":"Population pharmacokinetics in China: the dynamics of intravenous voriconazole in critically ill patients with pulmonary disease","volume":"38","author":"Chen","year":"2015","journal-title":"Biol Pharm Bull."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/AAC.00504-10","article-title":"Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients","volume":"54","author":"Han","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/11538690-000000000-00000","article-title":"Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients","volume":"50","author":"Han","year":"2011","journal-title":"Clin Pharmacokinet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/FTD.0000000000000425","article-title":"Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients","volume":"39","author":"Li","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/bcp.13595","article-title":"Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients","volume":"84","author":"Lin","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10096-008-0543-1","article-title":"Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies","volume":"27","author":"Nomura","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Voriconazole pharmacokinetics and therapeutic drug monitoring: a multi-center study","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin Microbiol Infect."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/13693786.2011.630039","article-title":"Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients","volume":"50","author":"Gomez-Lopez","year":"2012","journal-title":"Med Mycol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"e22011","DOI":"10.1002\/jcla.22011","article-title":"Development and validation of voriconazole concentration by LC-MS-MS: applied in clinical implementation","volume":"31","author":"Prommas","year":"2017","journal-title":"J Clin Lab Anal."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.dmpk.2015.12.005","article-title":"A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis","volume":"31","author":"Chuwongwattana","year":"2016","journal-title":"Drug Metab Pharmacokinet."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/ajkd.1998.v32.pm9669431","article-title":"Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients","volume":"32","author":"Bologa","year":"1998","journal-title":"Am J Kidney Dis."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jpen.1451","article-title":"Hypoalbuminemia: pathogenesis and clinical significance","volume":"43","author":"Peter","year":"2019","journal-title":"J Parenter Enteral Nutr."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","article-title":"Serum albumin: relationship to inflammation and nutrition","volume":"17","author":"Burl","year":"2004","journal-title":"Semin Dial."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0272-6386(00)70200-9","article-title":"C-reactive protein supersedes albumin in predicting mortality in hemodialysis patients","volume":"35","author":"Yeun","year":"2000","journal-title":"Am J Kidney Dis."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2152\/jmi.61.361","article-title":"Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study","volume":"61","author":"Ishida","year":"2014","journal-title":"J Med Invest."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1124\/dmd.113.052126","article-title":"Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association with gene expression","volume":"41","author":"Rieger","year":"2013","journal-title":"Drug Metab Dispos."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.114.062844","article-title":"Inflammation-associated MicroRNA-130b down-regulates cytochrome P450 activities and directly target CYP2C9","volume":"43","author":"Reiger","year":"2015","journal-title":"Drug Metab Dispos."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Atiken","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Alffenaar","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/AAC.02830-15","article-title":"Longitudinal analysis of the effect of inflammation on voriconazole trough concentration","volume":"60","author":"Alffenaar","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/AAC.04789-14","article-title":"Influence of inflammation on voriconazole metabolism","volume":"59","author":"Alffenaar","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/AAC.03820-14","article-title":"Inflammation is associated with voriconazole trough concentrations","volume":"58","author":"Alffenaar","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40780-016-0044-9","article-title":"A retrospective analysis of patient-specific factors on voriconazole clearance","volume":"2","author":"Dote","year":"2016","journal-title":"J Pharm Health Care Sci."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cca.2014.12.024","article-title":"Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungal in immunocompromised patients","volume":"441","author":"Naito","year":"2015","journal-title":"Clin Chim Acta."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1021\/tx500203s","article-title":"Role of protein-protein interaction in cytochrome P450-mediated drug metabolism and toxicity","volume":"27","author":"Sylie","year":"2014","journal-title":"Chem Res Toxicol."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2012.00318","article-title":"Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine","volume":"3","author":"Lee","year":"2013","journal-title":"Front Genet."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3947\/ic.2013.45.4.406","article-title":"Clinical impact of cytochrome P450 2C19 genotype on the treatment of invasive aspergillosis under routine therapeutic drug monitoring of voriconazole in a Korean population","volume":"45","author":"Kim","year":"2013","journal-title":"Infect Chemother."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11096-015-0143-y","article-title":"Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians","volume":"37","author":"Chawla","year":"2015","journal-title":"Int J Clin Pharm."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing","volume":"69","author":"Dolton","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cpt.1012","article-title":"Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults","volume":"104","author":"Mangal","year":"2018","journal-title":"Clin Pharmacol Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:16:09Z","timestamp":1692051369000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000799","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}